Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2018 Nov 26. doi: 10.1038/s41388-018-0579-3. [Epub ahead of print]

PMID:
30478447
2.

Distinct expression profiles and functions of Kindlins in breast cancer.

Azorin P, Bonin F, Moukachar A, Ponceau A, Vacher S, Bièche I, Marangoni E, Fuhrmann L, Vincent-Salomon A, Lidereau R, Driouch K.

J Exp Clin Cancer Res. 2018 Nov 26;37(1):281. doi: 10.1186/s13046-018-0955-4.

3.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2018 Nov 6. doi: 10.1158/1541-7786.MCR-18-0363. [Epub ahead of print]

PMID:
30401719
4.

VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX.

Bonin F, Taouis K, Azorin P, Petitalot A, Tariq Z, Nola S, Bouteille N, Tury S, Vacher S, Bièche I, Rais KA, Pierron G, Fuhrmann L, Vincent-Salomon A, Formstecher E, Camonis J, Lidereau R, Lallemand F, Driouch K.

BMC Biol. 2018 Oct 2;16(1):109. doi: 10.1186/s12915-018-0576-6.

5.

Emergence of boscalid-resistant strains of Erysiphe necator in French vineyards.

Cherrad S, Charnay A, Hernandez C, Steva H, Belbahri L, Vacher S.

Microbiol Res. 2018 Nov;216:79-84. doi: 10.1016/j.micres.2018.08.007. Epub 2018 Aug 11.

PMID:
30269859
6.

MT1-MMP targeting to endolysosomes is mediated by upregulation of flotillins.

Planchon D, Rios Morris E, Genest M, Comunale F, Vacher S, Bièche I, Denisov EV, Tashireva LA, Perelmuter VM, Linder S, Chavrier P, Bodin S, Gauthier-Rouvière C.

J Cell Sci. 2018 Sep 5;131(17). pii: jcs218925. doi: 10.1242/jcs.218925.

PMID:
30111578
7.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.

Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.

Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

8.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
9.

Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.

Castagnino A, Castro-Castro A, Irondelle M, Guichard A, Lodillinsky C, Fuhrmann L, Vacher S, Agüera-González S, Zagryazhskaya-Masson A, Romao M, El Kesrouani C, Noegel AA, Dubois T, Raposo G, Bear JE, Clemen CS, Vincent-Salomon A, Bièche I, Chavrier P.

Oncogene. 2018 Dec;37(50):6425-6441. doi: 10.1038/s41388-018-0422-x. Epub 2018 Jul 31.

PMID:
30065298
10.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
11.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.

Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.

12.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

13.

The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Sep;246(1):103-114. doi: 10.1002/path.5104. Epub 2018 Aug 7.

PMID:
29876931
14.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

PMID:
29844016
15.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

16.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

17.

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.

Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

18.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

PMID:
29463559
19.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

20.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
21.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M.

PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.

22.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

23.

Comparative Genomics of Bacillus amyloliquefaciens Strains Reveals a Core Genome with Traits for Habitat Adaptation and a Secondary Metabolites Rich Accessory Genome.

Belbahri L, Chenari Bouket A, Rekik I, Alenezi FN, Vallat A, Luptakova L, Petrovova E, Oszako T, Cherrad S, Vacher S, Rateb ME.

Front Microbiol. 2017 Aug 3;8:1438. doi: 10.3389/fmicb.2017.01438. eCollection 2017.

24.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

25.

Exposure of marine mussels to diclofenac: modulation of prostaglandin biosynthesis.

Courant F, Arpin-Pont L, Bonnefille B, Vacher S, Picot-Groz M, Gomez E, Fenet H.

Environ Sci Pollut Res Int. 2018 Mar;25(7):6087-6094. doi: 10.1007/s11356-017-9228-6. Epub 2017 May 21.

PMID:
28528506
26.

Clinical value of R-spondins in triple-negative and metaplastic breast cancers.

Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.

Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.

27.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
28.

Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration.

Bosch Grau M, Masson C, Gadadhar S, Rocha C, Tort O, Marques Sousa P, Vacher S, Bieche I, Janke C.

J Cell Sci. 2017 Mar 1;130(5):938-949. doi: 10.1242/jcs.199091. Epub 2017 Jan 19.

29.

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Tury S, Becette V, Assayag F, Vacher S, Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F, Callens C.

Oncotarget. 2016 Dec 20;7(51):85124-85141. doi: 10.18632/oncotarget.13200.

30.

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Chakhtoura Z, Laki F, Bernadet M, Cherifi I, Chiche A, Pigat N, Bernichtein S, Courtillot C, Boutillon F, Bièche I, Vacher S, Tanguy ML, Bissery A, Grouthier V, Camparo P, Foretz M, Do Cruzeiro M, Pierre R, Rakotozafy F, Tichet J, Tejedor I, Guidotti JE, Sigal-Zafrani B, Goffin V, Touraine P.

J Clin Endocrinol Metab. 2016 Nov;101(11):4449-4460. Epub 2016 Aug 30.

PMID:
27575941
31.

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.

Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, Vacher S, Couturier J, Mariani O, Terrier P, Bièche I.

Oncotarget. 2016 Dec 20;7(51):84428-84438. doi: 10.18632/oncotarget.12991.

32.

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts.

Assayag F, Nicolas A, Vacher S, Dehainault C, Bieche I, Meseure D, Aerts I, Cassoux N, Houdayer C, Doz F, Decaudin D.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4916-4926. doi: 10.1167/iovs.15-18725.

PMID:
27654418
33.

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.

Deniziaut G, Tille JC, Bidard FC, Vacher S, Schnitzler A, Chemlali W, Trémoulet L, Fuhrmann L, Cottu P, Rouzier R, Bièche I, Vincent-Salomon A.

Oncotarget. 2016 Nov 8;7(45):73337-73346. doi: 10.18632/oncotarget.11819.

34.

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Guéret M.

Clin Cancer Res. 2017 Apr 15;23(8):2116-2126. doi: 10.1158/1078-0432.CCR-16-0626. Epub 2016 Sep 6.

35.

Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I.

Cancer Microenviron. 2016 Dec;9(2-3):107-118. doi: 10.1007/s12307-016-0186-1. Epub 2016 Jul 9.

36.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

37.

Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.

Sablin MP, Dubot C, Klijanienko J, Vacher S, Ouafi L, Chemlali W, Caly M, Sastre-Garau X, Lappartient E, Mariani O, Rodriguez J, Jouffroy T, Girod A, Calugaru V, Hoffmann C, Lidereau R, Berger F, Kamal M, Bieche I, Le Tourneau C.

Oncotarget. 2016 Jul 26;7(30):47418-47430. doi: 10.18632/oncotarget.10163.

38.

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.

Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, Nicolas A, De Koning L, Pasmant E, Callens C, Lidereau R, Morillon A, Bieche I.

Br J Cancer. 2016 Jun 14;114(12):1395-404. doi: 10.1038/bjc.2016.123. Epub 2016 May 12.

39.

Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.

Meseure D, Vacher S, Alsibai KD, Nicolas A, Chemlali W, Caly M, Lidereau R, Pasmant E, Callens C, Bieche I.

Mol Cancer Res. 2016 Jul;14(7):623-33. doi: 10.1158/1541-7786.MCR-15-0418. Epub 2016 Apr 21.

40.

CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Thion MS, Tézenas du Montcel S, Golmard JL, Vacher S, Barjhoux L, Sornin V, Cazeneuve C, Bièche I, Sinilnikova O, Stoppa-Lyonnet D, Durr A, Humbert S.

Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.

41.

Arpin downregulation in breast cancer is associated with poor prognosis.

Lomakina ME, Lallemand F, Vacher S, Molinie N, Dang I, Cacheux W, Chipysheva TA, Ermilova VD, de Koning L, Dubois T, Bièche I, Alexandrova AY, Gautreau A.

Br J Cancer. 2016 Mar 1;114(5):545-53. doi: 10.1038/bjc.2016.18. Epub 2016 Feb 11.

42.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

43.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Hatem R, Labiod D, Château-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E.

Int J Cancer. 2016 May 15;138(10):2510-21. doi: 10.1002/ijc.29974. Epub 2016 Jan 6.

44.

Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales.

Pignot G, Le Goux C, Bieche I, Vacher S, Barry de Longchamps N, Sibony M, Zerbib M.

Prog Urol. 2015 Nov;25(13):762. doi: 10.1016/j.purol.2015.08.096. French. No abstract available.

PMID:
26544291
45.

IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production.

Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G.

Oncotarget. 2015 Oct 6;6(30):29034-47. doi: 10.18632/oncotarget.4732.

46.

Unraveling the Role of Huntingtin in Breast Cancer Metastasis.

Thion MS, McGuire JR, Sousa CM, Fuhrmann L, Fitamant J, Leboucher S, Vacher S, du Montcel ST, Bièche I, Bernet A, Mehlen P, Vincent-Salomon A, Humbert S.

J Natl Cancer Inst. 2015 Aug 20;107(10). pii: djv208. doi: 10.1093/jnci/djv208. Print 2015 Oct.

PMID:
26293574
47.

Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.

Chiker S, Pennaneach V, Loew D, Dingli F, Biard D, Cordelières FP, Gemble S, Vacher S, Bieche I, Hall J, Fernet M.

Cell Cycle. 2015;14(19):3066-78. doi: 10.1080/15384101.2015.1078020.

48.

MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.

Di Benedetto M, Toullec A, Buteau-Lozano H, Abdelkarim M, Vacher S, Velasco G, Christofari M, Pocard M, Bieche I, Perrot-Applanat M.

Br J Cancer. 2015 Sep 1;113(5):773-85. doi: 10.1038/bjc.2015.267. Epub 2015 Jul 21.

49.

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C.

BMC Cancer. 2015 Jul 5;15:499. doi: 10.1186/s12885-015-1505-5.

50.

p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Lodillinsky C, Infante E, Guichard A, Chaligné R, Fuhrmann L, Cyrta J, Irondelle M, Lagoutte E, Vacher S, Bonsang-Kitzis H, Glukhova M, Reyal F, Bièche I, Vincent-Salomon A, Chavrier P.

Oncogene. 2016 Jan 21;35(3):344-57. doi: 10.1038/onc.2015.87. Epub 2015 Apr 20.

PMID:
25893299

Supplemental Content

Loading ...
Support Center